Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from atypical antipsychotics to bifeprunox in schizophrenia or schizoaffective disorder
2006-004972-11Phase 3Terminated
- Sponsor
- Solvay
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bifeprunox in schizophrenia and schizoaffective disorder (2 arms), sponsored by Solvay. Primary endpoint: Safety and tolerability of switching to bifeprunox. Started Jan 2007; status: terminated.
02
Drugs
bifeprunox
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2006-004972-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004972-11.